Crinetics Pharmaceuticals CRNX Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's operating lease liabilities (current)?
- Crinetics Pharmaceuticals (CRNX) reported operating lease liabilities (current) of $6.54M in Q1 2026.
- How has Crinetics Pharmaceuticals's operating lease liabilities (current) changed year-over-year?
- Crinetics Pharmaceuticals's operating lease liabilities (current) decreased by 5.0% year-over-year, from $6.88M to $6.54M.
- What is the long-term trend for Crinetics Pharmaceuticals's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Crinetics Pharmaceuticals's operating lease liabilities (current) has grown at a 50.7% compound annual growth rate (CAGR), from $835K to $6.49M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.